Abstract
Background
A previous study indicated that gut microbiota changed notably in Graves’ orbitopathy (GO) patients as compared to controls. However, the characteristics of intestinal bacteria in Graves’ disease (GD) and GO are unclear.
Objective
The present study aimed to identify specific intestinal bacteria of GD and GO, respectively.
Methods
The gut microbial communities of the fecal samples of 30 GD patients without GO, 33 GO subjects, and 32 healthy subjects were analyzed and compared by 16S rRNA gene sequencing.
Results
At the phylum level, the proportion of Deinococcus-Thermus and Chloroflexi was decreased significantly in GO patients as compared to GD. At the genus level, the proportion of Subdoligranulum and Bilophila was increased while that of Blautia, Anaerostipes, Dorea, Butyricicoccus, Romboutsia, Fusicatenibacter, unidentified_ Lachnospiraceae, unidentified_Clostridiales, Collineslla, Intestinibacter, and Phascolarctobacterium was decreased in the GO group as compared to the GD group. Random forest analysis was used for the identification of specific intestinal microbiota, and Deinococcus-Thermus, Cyanobacteria and Chloroflexi were ranked in the top ten according to their contributions to sample classification. Moreover, compared to the control, there were multiple gut bacterial enrichment metabolic pathways in GO and GD patients, including nucleotide metabolism, enzyme family, and energy metabolism. Compared to GO, the only enrichment metabolic pathway found in GD was the viral protein family.
Conclusions
This study highlighted the significant differences in the intestinal microbiota and predictive functions of GD with GO, thereby providing new insights into the role of the gut bacteria that might contribute to the development of GO in GD patients.
Similar content being viewed by others
Abbreviations
- GO:
-
Graves’ orbitopathy
- GD:
-
Graves’ disease
- HT:
-
Hashimoto Thyroiditis
- TRAb:
-
Thyrotropin receptor antibody
- IBD:
-
Inflammatory bowel disease
- SLE:
-
Systemic lupus erythematosus
- RA:
-
Rheumatoid arthritis
- AITD:
-
Autoimmune thyroid diseases
- TPOAb:
-
Thyroperoxidase antibody
- TGAb:
-
Antithyroglobulin antibody
- OTU:
-
Operational taxonomy units
- KEGG:
-
Kyoto Encyclopedia of Genes and Genomes
- PCoA:
-
Principal coordinate analysis
- LDA:
-
Linear discriminant analysis
- LEfSe:
-
LDA effect size
- MDG:
-
Mean Decrease Gini
References
Ehlers M, Schott M, Allelein S (2019) Graves' disease in clinical perspective. Front Biosci (Landmark Ed) 24:35–47
Smith TJ (2017) TSHR as a therapeutic target in Graves' disease. Expert Opin Ther Targets 21(4):427–432. https://doi.org/10.1080/14728222.2017.1288215
Bahn RS (2010) Graves' ophthalmopathy. N Engl J Med 362(8):726–738. https://doi.org/10.1056/NEJMra0905750
Drui D, Du Pasquier FL, Vignal Clermont C, Daumerie C (2018) Graves' orbitopathy: Diagnosis and treatment. Ann Endocrinol (Paris). https://doi.org/10.1016/j.ando.2018.08.005
Wiersinga WM (2017) Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy. Lancet Diabetes Endocrinol 5(2):134–142. https://doi.org/10.1016/S2213-8587(16)30046-8
Kataoka K (2016) The intestinal microbiota and its role in human health and disease. J Med Invest 63(1–2):27–37. https://doi.org/10.2152/jmi.63.27
Partida-Rodriguez O, Serrano-Vazquez A, Nieves-Ramirez ME, Moran P, Rojas L, Portillo T, Gonzalez E, Hernandez E, Finlay BB, Ximenez C (2017) Human intestinal microbiota: interaction between parasites and the host immune response. Arch Med Res 48(8):690–700. https://doi.org/10.1016/j.arcmed.2017.11.015
Virili C, Centanni M (2015) Does microbiota composition affect thyroid homeostasis? Endocrine 49(3):583–587. https://doi.org/10.1007/s12020-014-0509-2
Virili C, Fallahi P, Antonelli A, Benvenga S, Centanni M (2018) Gut microbiota and Hashimoto's thyroiditis. Rev Endocr Metab Disord 19(4):293–300. https://doi.org/10.1007/s11154-018-9467-y
Ishaq HM, Mohammad IS, Shahzad M, Ma C, Raza MA, Wu X, Guo H, Shi P, Xu J (2018) Molecular alteration analysis of human gut microbial composition in Graves' disease patients. Int J Biol Sci 14(11):1558–1570. https://doi.org/10.7150/ijbs.24151
Zhao F, Feng J, Li J, Zhao L, Liu Y, Chen H, Jin Y, Zhu B, Wei Y (2018) Alterations of the gut microbiota in Hashimoto's thyroiditis patients. Thyroid 28(2):175–186. https://doi.org/10.1089/thy.2017.0395
Shi TT, Xin Z, Hua L, Zhao RX, Yang YL, Wang H, Zhang S, Liu W, Xie RR (2019) Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study. J Endocrinol Invest 42(8):967–978. https://doi.org/10.1007/s40618-019-1010-9
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM; European Group on Graves O (2016) The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the management of Graves' orbitopathy. Eur Thyroid J 5(1):9–26. https://doi.org/10.1159/000443828
Ji DY, Park SH, Park SJ, Kim KH, Ku CR, Shin DY, Yoon JS, Lee DY, Lee EJ (2018) Comparative assessment of Graves' disease and main extrathyroidal manifestation, Graves' ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue. Sci Rep 8(1):9262. https://doi.org/10.1038/s41598-018-27600-0
Allali I, Arnold JW, Roach J, Cadenas MB, Butz N, Hassan HM, Koci M, Ballou A, Mendoza M, Ali R, Azcarate-Peril MA (2017) A comparison of sequencing platforms and bioinformatics pipelines for compositional analysis of the gut microbiome. BMC Microbiol 17(1):194. https://doi.org/10.1186/s12866-017-1101-8
Han Z, Li K, Shahzad M, Zhang H, Luo H, Qiu G, Lan Y, Wang X, Mehmood K, Li J (2017) Analysis of the intestinal microbial community in healthy and diarrheal perinatal yaks by high-throughput sequencing. Microb Pathog 111:60–70. https://doi.org/10.1016/j.micpath.2017.08.025
Piotrowska A, Gosiewski T, Bulanda M, Brzychczy-Wloch M (2016) Using of the 16S rDNA sequencing for identification of Lactobacillus species. Med Dosw Mikrobiol 68(1):5–11
Zhou L, Ni Z, Cheng W, Yu J, Sun S, Zhai D, Yu C, Cai Z (2020) Characteristic gut microbiota and predicted metabolic functions in women with PCOS. Endocr Connect 9(1):63–73. https://doi.org/10.1530/EC-19-0522
Loke MF, Chua EG, Gan HM, Thulasi K, Wanyiri JW, Thevambiga I, Goh KL, Wong WF, Vadivelu J (2018) Metabolomics and 16S rRNA sequencing of human colorectal cancers and adjacent mucosa. PLoS ONE 13(12):e0208584. https://doi.org/10.1371/journal.pone.0208584
Ritari J, Salojarvi J, Lahti L, de Vos WM (2015) Improved taxonomic assignment of human intestinal 16S rRNA sequences by a dedicated reference database. BMC Genomics 16:1056. https://doi.org/10.1186/s12864-015-2265-y
Zhou L, Li X, Ahmed A, Wu D, Liu L, Qiu J, Yan Y, Jin M, Xin Y (2014) Gut microbe analysis between hyperthyroid and healthy individuals. Curr Microbiol 69(5):675–680. https://doi.org/10.1007/s00284-014-0640-6
Griffiths E, Gupta RS (2007) Identification of signature proteins that are distinctive of the Deinococcus-Thermus phylum. Int Microbiol 10(3):201–208
Kim CY, Lee HJ, Chae MK, Byun JW, Lee EJ, Yoon JS (2015) Therapeutic effect of resveratrol on oxidative stress in Graves' orbitopathy orbital fibroblasts. Invest Ophthalmol Vis Sci 56(11):6352–6361. https://doi.org/10.1167/iovs.15-16870
Abusleme L, Dupuy AK, Dutzan N, Silva N, Burleson JA, Strausbaugh LD, Gamonal J, Diaz PI (2013) The subgingival microbiome in health and periodontitis and its relationship with community biomass and inflammation. ISME J 7(5):1016–1025. https://doi.org/10.1038/ismej.2012.174
Lu W, Feng Y, Jing F, Han Y, Lyu N, Liu F, Li J, Song X, Xie J, Qiu Z, Zhu T, Routy B, Routy JP, Li T, Zhu B (2018) Association between gut microbiota and CD4 recovery in HIV-1 infected patients. Front Microbiol 9:1451. https://doi.org/10.3389/fmicb.2018.01451
Rivera-Pinto J, Egozcue JJ, Pawlowsky-Glahn V, Paredes R, Noguera-Julian M, Calle ML (2018) Balances: a new perspective for microbiome analysis. mSystems 3(4). https://doi.org/10.1128/mSystems.00053-18
Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17(12):1519–1528. https://doi.org/10.3748/wjg.v17.i12.1519
Di Segni A, Braun T, BenShoshan M, Farage Barhom S, Glick Saar E, Cesarkas K, Squires JE, Keller N, Haberman Y (2018) Guided protocol for fecal microbial characterization by 16S rRNA-amplicon sequencing. J Vis Exp (133). https://doi.org/10.3791/56845
Asshauer KP, Wemheuer B, Daniel R, Meinicke P (2015) Tax4Fun: predicting functional profiles from metagenomic 16S rRNA data. Bioinformatics 31(17):2882–2884. https://doi.org/10.1093/bioinformatics/btv287
Ashton JJ, Colquhoun CM, Cleary DW, Coelho T, Haggarty R, Mulder I, Batra A, Afzal NA, Beattie RM, Scott KP, Ennis S (2017) 16S sequencing and functional analysis of the fecal microbiome during treatment of newly diagnosed pediatric inflammatory bowel disease. Medicine (Baltimore) 96(26):e7347. https://doi.org/10.1097/MD.0000000000007347
Struja T, Kutz A, Fischli S, Meier C, Mueller B, Recher M, Schuetz P (2017) Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease. BMC Med 15(1):174. https://doi.org/10.1186/s12916-017-0939-9
Yamashita S, Izumi M, Morita S, Hirayu H, Tanabe T, Taura M, Sato K, Morimoto I, Okamoto S, Nagataki S (1982) Plasma cAMP and cGMP concentrations in outpatients with Graves' disease and chronic thyroiditis. Nihon Naibunpi Gakkai Zasshi 58(12):1498–1504. https://doi.org/10.1507/endocrine1927.58.12_1498
Yagura T, Nagata I, Kuma K, Uchino H (1985) Increased cyclic nucleotide phosphodiesterase (PDE) and calmodulin activities in soluble fraction of Graves' thyroid: analysis of increase in Ca+2 dependence of PDE activities. J Clin Endocrinol Metab 60(6):1180–1186. https://doi.org/10.1210/jcem-60-6-1180
Wang X, Xu K, Chen S, Li Y, Li M (2018) Role of interleukin-37 in inflammatory and autoimmune diseases. Iran J Immunol 15(3):165–174. https://doi.org/10.22034/IJI.2018.39386
Cheng CW, Yang SF, Wang YH, Fang WF, Lin YC, Tang KT, Lin JD (2019) Associations of secreted phosphoprotein 1 and B lymphocyte kinase gene polymorphisms with autoimmune thyroid disease. Eur J Clin Invest 49(3):e13065. https://doi.org/10.1111/eci.13065
Jaspan JB, Luo H, Ahmed B, Tenenbaum S, Voss T, Sander DM, Bollinger K, Baquet T, Garry RF (1995) Evidence for a retroviral trigger in Graves' disease. Autoimmunity 20(2):135–142. https://doi.org/10.3109/08916939509001938
Leite JL, Bufalo NE, Santos RB, Romaldini JH, Ward LS (2010) Herpesvirus type 7 infection may play an important role in individuals with a genetic profile of susceptibility to Graves' disease. Eur J Endocrinol 162(2):315–321. https://doi.org/10.1530/EJE-09-0719
Tozzoli R, Barzilai O, Ram M, Villalta D, Bizzaro N, Sherer Y, Shoenfeld Y (2008) Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology. Autoimmun Rev 8(2):112–115. https://doi.org/10.1016/j.autrev.2008.07.013
Kuang M, Wang S, Wu M, Ning G, Yao Z, Li L (2010) Expression of IFNalpha-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease. Mol Cell Endocrinol 319(1–2):23–29. https://doi.org/10.1016/j.mce.2009.12.006
Merrill SJ, Mu Y (2015) Thyroid autoimmunity as a window to autoimmunity: an explanation for sex differences in the prevalence of thyroid autoimmunity. J Theor Biol 375:95–100. https://doi.org/10.1016/j.jtbi.2014.12.015
Acknowledgements
The authors thank all the participants and staff involved in the study.
Funding
This work was supported by the Beijing Municipal Hospital Research and Development Program (PX2016063), the Expert Promotion Program of Beijing Health Systems (2015-3-017) to Zhong Xin, and the Foundation of Beijing Tongren Hospital (2015-YJJ-ZZL-006) to Ting-Ting Shi.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interests.
Ethics approval
The study was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University. All procedures were performed in the study in accordance with the 1964 Helsinki declaration and its later amendments.
Informed consent
Informed written consents were obtained from all participants included in this study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shi, TT., Xin, Z., Hua, L. et al. Comparative assessment of gut microbial composition and function in patients with Graves’ disease and Graves’ orbitopathy. J Endocrinol Invest 44, 297–310 (2021). https://doi.org/10.1007/s40618-020-01298-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-020-01298-2